Printer Friendly

Nicox signs license agreement with Fera Pharmaceuticals.

M2 EQUITYBITES-November 11, 2015-Nicox signs license agreement with Fera Pharmaceuticals


Nicox, a France-based pharmaceutical company, has signed a license agreement with Fera Pharmaceuticals.

It was reported yesterday that the contract has been signed to develop and commercialise the company's naproxcinod, a cyclooxygenase-inhibiting nitric oxide-donating anti-inflammatory candidate, in the US.

Fera Pharmaceuticals will initially concentrate on the signs and symptoms of osteoarthritis. Nicox already completed a clinical program for naproxcinod in osteoarthritis, including three phase 3 trials with more than 2,700 patients. The company aims to seek advice from the United States Food and Drug Administration with regard to the further clinical work needed before submitting a new drug application for naproxcinod. The transaction needs Fera to pay around USD35m in sales-based milestones to Nicox. It also includes 7% royalties depending on net sales of naproxcinod in the US.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 11, 2015
Previous Article:Jernigan Capital declares dividend of USD0.35 per share for Q4 2015.
Next Article:Ocata Therapeutics to be acquired by Astellas Pharma.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |